Company ProfilePremium

Cosmax, Inc.

Company Profile Analysis

Ticker: 192820.KS코스맥스 주식회사

ESOMAR 23 Corporate BadgeISO Certifications Badge
Cosmax, Inc. - Company showcase

Year Founded & Workforce

1992

Cosmax, Inc. logo

Cosmax, Inc. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Cosmax, Inc. Overview

Cosmax, Inc. is the world's largest cosmetics original development manufacturer (ODM) by revenue. It formulates, develops and mass-produces skincare, makeup, hair, body and sun-care products that other companies sell under their own brands. Its client base spans global multinationals such as L'Oréal, a supplier relationship since 2004, and thousands of fast-moving Korean, Chinese, Southeast Asian and US "indie" brands. FY2025 revenue was a record KRW 2,398.8 bn (about USD 1.66 bn), and operating profit was KRW 195.8 bn. Cosmax runs production in Korea, China, the United States, Indonesia, Thailand and, since April 2026, Italy, with stated capacity of about 2.69 bn units a year. The equity story rests on the structural globalisation of K-beauty. Cosmax acts as an outsourced R&D and manufacturing engine behind much of it, and it is widening its model from pure ODM into raw-material design, OBM brand-building services, and co-innovation with L'Oréal.


Company self-description

Cosmax describes itself as a global cosmetics R&D and production (ODM) company that researches, develops and manufactures cosmetics in Korea and overseas. In its DART filing the company states its business as cosmetics, customised cosmetics and other, covering skincare, base makeup, colour makeup, herbal cosmetics, fragrance and hair care (summary of the company profile used in Korean brokerage data). In its 2026 investor materials the company describes supplying more than 4,000 brands in more than 100 countries, with over 90% of sales from ODM contracts (Q2 2026 earnings summary via Quartr). Press materials also cite about 5,000 client companies (Kukinews, Dec 2025; Fortune 2026).

Business model

ODM (core, >90% of sales): Cosmax develops the formula, often proposing finished concepts, textures and claims. It then produces the product at its own plants for the brand owner. Revenue is recognised per unit shipped. Pricing is negotiated product by product and is not publicly disclosed.

OEM: Cosmax manufactures to a formula supplied by the client. This share has declined over time; in the US the ODM share reportedly reached about 80% by 2024 (Dealsite, Sep 2024).

OBM (original brand manufacturing): a newer service layer in which Cosmax supports brand planning as well as R&D and manufacturing. It is active in Thailand since H2 2025 and is being extended group-wide (Dealsite, Nov 2025; Herald Business, 2026).

Ancillary platforms: an export-support platform that helps clients with customs, tariffs and logistics for direct exports; a packaging sourcing platform ("Cosmax Package.com"); and customised-cosmetics/AI personalisation capabilities (TheVC; Newdaily, Mar 2025; Kukinews, May 2025).

Revenue model mix: effectively 100% product revenue (manufactured goods). There is no material subscription, licensing or service revenue line in the sources reviewed.

Value-chain position

Cosmax sits between raw-material and packaging suppliers upstream and brand owners and retailers downstream. It manages about 200 strategic suppliers under an ESG programme (Kukinews, Mar 2025). It is pushing upstream into proprietary raw-material development, which the company says cuts costs by about 30% versus imported materials (Sidae, Mar 2026).

Customer types and end-markets

Global multinationals: L'Oréal (since 2004); Fortune also names Shiseido, Yves Saint Laurent and Lancôme.

Korean indie and mid-size brands: brokers name APR, The Founders, Mediheal, Jung Saem Mool and Clio among recent growth drivers (Hana Securities, Jul 2026; SK Securities, Oct 2026).

Chinese domestic brands: historically Florasis (Huaxizi), Perfect Diary and Ziranzhai (Dealsite, Mar 2022).

Southeast Asian brands: for example Mistine in Thailand (Maeil Business, Jun 2018).

US indie brands: West Coast clients are served through a California sales office (FY2025 results release).

End-markets are prestige and mass skincare, colour cosmetics, sun care, hair and body care, and derma/medical-device cosmetics (via Keminova). Products sell through online, Health & Beauty stores, duty-free, modern and general trade in Southeast Asia, and export channels.

Independent characterisation

Cosmax is best understood as a capacity-plus-formulation-library platform whose growth tracks two things: (i) the number of brands launching products, especially asset-light indie brands that cannot afford in-house R&D, and (ii) the speed at which Korean-designed products are exported. The Korean entity is the profit engine (KRW 154.6 bn of the group's KRW 195.8 bn FY2025 operating profit). Overseas subsidiaries have historically diluted margins, and the US has diluted capital as well. The investment case in 2026 is shifting from "Korea carries the group" to "all regions contribute", following the US unit's first quarterly operating profit in Q2 2026.

Strategy

Stated strategy (paraphrased)

2026 management keyword: adding a premium to customer value through Cosmax's own capabilities (Sidae, Feb 2026).

Stated priorities: - Build overwhelming leadership in strategic categories, especially sun care and base makeup.

  • Expand joint sales across global subsidiaries.

  • Pursue emerging markets in the Middle East, Latin America and Africa.

  • Use the Indonesian and Thai subsidiaries to reach Vietnam and India.

  • Grow with K-indie brands.

  • Consolidate the "world No. 1 ODM" position (FY2025 results release).

Business-model evolution: from order-taking to a "total solution" partner. This combines proprietary raw-material development (about 30% cost saving versus imports), ESG and global-certification consulting, and OBM brand support. R&D is held at 5% or more of sales (Sidae, Mar 2026).

Strategic initiatives, last 24 months

InitiativeDateDetailsStatus
Thailand capacity triplingMar 2025 – Sep 2026KRW 56 bn / THB 1.5 bn; 36,000 m² plant; up to 230 m unitsScheduled start Sep 2026
Korea capacity expansionJan 2025 – end-2025+20% (Jan 2025), +30% targeted by end-2025Partial verification only
US turnaround programme2024–2026West Coast sales office, ODM share about 80%, fixed-cost reduction, OTC Lab for sunscreenFirst quarterly operating profit in Q2 2026
Europe entry (Keminova)Feb–Apr 202651% stake; "Made in Italy" positioning; R&D reorganised; "Keminova Academy" plannedPost-merger integration under way (ICE, Jul 2026)
L'Oréal co-innovation MOUSep 2026Global product development, ingredients and actives, sensory signatures and formatsMOU (non-binding)
China structure clean-up2023–2026Buy-out of financial investors; RCPS→CB (2025); early CB redemption and IPO withdrawal (2026)Completed / in progress
Value-up planNov 202530% shareholder return on standalone net income through 2028; more predictable dividendsIn force; FY2025 DPS +43.5%
Renewable energy / carbonMay 2026PPA with Hanwha Solutions (Q CELLS) for 10.4 GWh a year; about 40% renewable share at Hwaseong and Pyeongtaek; product LCA systemSigned
Supplier ESG programmeMar 2025About 200 suppliers: ESG assessments and audits, carbon inventory support, supplier carbon-neutral guidelineOngoing
AI personalisation2,025Hyper-personalised cosmetics (shampoo first; lip and foundation next)Early stage

Medium-term targets and guidance

Financial guidance: Cosmax provides internal guidance (Kyobo, Oct 2026, says Korea and US were tracking above guidance in Q3 2026), but specific numerical medium-term targets were not found in the sources reviewed.

Capital return: 30% shareholder return ratio on standalone net income through 2028 (Value-up Plan).

Earlier target (2024 NDR): a Cosmax China listing in 2026 (Yuanta, Nov 2024). This has been withdrawn (2026).

Products & Services

Cosmax does not publish a client-facing price list or product-by-product sales. The catalog below is organised by category and capability. Named products are client-branded items that Cosmax has been publicly identified as manufacturing. Pricing is not publicly disclosed for any line; ODM pricing is negotiated per SKU.

Skincare (about 64% of Korea Q1 2026 sales, versus 53% in Q1 2025 — Eugene, May 2026)

Product lineDescription / capabilitiesTarget customerNotes / flagship evidence
Creams, serums, essences, tonersCore basic skincare with proprietary actives and texture librariesIndie and MNC brands in Korea, China, US, SEASK Securities (Apr 2026) says many leading K-beauty skincare SKUs are Cosmax-made
Hydrogel / gel mask packsHigh-volume sheet and hydrogel masks; lower margin than creamsKorean indie brands for exportIdentified as a Q3–Q4 2025 growth driver; profitability improved in 2026 (Byline; company release, Aug 2026)
Sun care (sunscreens, sun serums, sun sticks)Texture innovation such as "sun serum" formats; inorganic UV filter R&D (zinc oxide, titanium dioxide national R&D project, 2024)Global brands; US OTC-regulated marketKorea sun-care sales +80% YoY in Q3 2025 (Byline); +50% to about KRW 40 bn in Q2 2025 (Daishin). OTC Lab created for US sunscreen (Dealsite, Sep 2024)
Multi-balms / stick formatsSolid stick skincareKorean brands"Kahi Multi Balm" cited as a 2021 hit product (Dealsite, Mar 2022)
CleansersIncluding a cream-to-oil cleanser composition (2025 patent filing)AllCosinKorea patent digest (Jul 2025)
Derma / medical-device cosmeticsEuropean derma cosmetics, medical-device-classified productsItalian derma brands and pharma companiesVia Keminova (Brescia) from Apr 2026

Base makeup

Product lineDescriptionTarget customerNotes
Cushion compactsSignature K-beauty base formatChina, Korea, globalShanghai growth in cushions and foundations, Q2 2026 (Sateconomy, Aug 2026)
Foundations, primersLiquid and cream basesMNC and indieNamed a strategic category for 2026 alongside sun care (Sidae, Feb 2026)

Colour cosmetics (about 36% of Korea Q1 2026 sales)

Product lineDescriptionTarget customerNotes
Lip (tints, lipsticks)Broad shade and texture libraryKorea, China, US indieChina lip and blusher growth in Q2 2026
Cheek / blusher, eyePowders, creamsKorean brands such as Jung Saem Mool and ClioSK Securities (Oct 2026) cites strong colour orders in Q3 2026
US colour (New Jersey)Colour cosmetics plant from the Nu-World acquisitionUS mass and indieNu-World made "Hard Candy" and supplied Walmart doors (CNC News, 2017)

Hair & body care

New focus categories from 2025. The company reported meaningful results in hair and body in Q4 2025 (Hankyung Magazine, Feb 2026). US demand is concentrated in body care and sun care (Quartr Q2 2025 summary). Keminova adds haircare expertise.

Herbal (한방) cosmetics and fragrance

Listed in the company's business description. No revenue split disclosed.

Customised / personalised cosmetics

An AI-driven personalisation platform. The shampoo configurator alone allows 12.6 m combinations, with plans to extend to lipsticks and foundations (Kukinews, May 2025). This is a reported segment line ("customised cosmetics"). Revenue is not disclosed and is believed to be small.

Services and platforms

ServiceDescriptionLaunch / status
Full-service ODMConcept, formulation, stability and efficacy testing, regulatory dossiers, productionCore since the 1990s
OBM supportBrand planning in addition to R&D and manufacturingThailand from H2 2025; expanding group-wide
Export support platformCustoms, tariffs and logistics support for clients' direct exportsOperating (TheVC news feed)
Cosmax Package.comOnline packaging-sample sourcing for clients and suppliersOperating (Newdaily, Mar 2025)
Raw-material co-developmentProprietary ingredients proposed to clients ("reverse proposals")Strategic priority 2026 (Sidae, Mar 2026)
Global joint salesCross-subsidiary account coverage; "Loco Project" low-cost lines in Indonesia/China2025–2026 (Cosmax Q4 2025 IR; Eugene)

Out-of-scope group businesses (not consolidated in 192820)

Health functional foods (Cosmax NBT), pet products (Cosmax Pet, new Jeungpyeong plant), and holding-level beauty-tech ventures (Cosmax BTI). They are noted for context only.

Financial Narrative

Income statement

Sources: FY2021 (Dealsite, Mar 2022); FY2022 (Dealsite, Mar 2023/Mar 2024; DART-based data via ETFShopping); FY2023 (Dealsite, Mar 2024); FY2024–FY2025 (Cosmax FY2025 release, Feb 2026; dividend disclosure, Mar 2026). EBITDA, EPS and controlling NI from Hanwha Investment & Securities (Jan 2025, May 2026). Eugene reports FY2023 EPS of KRW 5,034, a minor discrepancy.

Revenue CAGR FY2021–FY2025: 10.8% (derived). Operating income CAGR: 12.4% (derived).

Quarterly trajectory (most recent 7 quarters)

Sources: Cosmax IR decks (Feb 2025, Nov 2025, Feb 2026); Quartr summaries; Dealsite; Shinhan (Feb 2026); Eugene (May 2026); company release (Aug 2026). Q4 2025 net profit is derived as FY2025 KRW 131.1 bn minus Q1–Q3.

H1 2026: revenue KRW 1,476.9 bn (+22%), operating profit KRW 126.8 bn (+13%), net income KRW 93.8 bn.

Balance sheet

Sources: Valueline (consolidated balance sheet, updated to Q1 2026); Yuanta (Apr 2026); Hanwha (May 2026); Daum Finance BPS of KRW 49,196 × 11.35 m shares.

Borrowing definitions differ materially across brokers. For FY2024, Yuanta's September 2025 report showed KRW 878.5 bn and its April 2026 report KRW 968.5 bn. Kyobo shows KRW 739 bn (FY2024) and KRW 813 bn (FY2025). The differences likely reflect the treatment of lease liabilities and of Cosmax East's RCPS/CB, which were classified as debt.

Latest (31 Mar 2026): total assets KRW 2,516.0 bn; current assets KRW 1,265.3 bn; cash KRW 369.3 bn (Valueline).

Cash flow

Known data points:

  • No share buyback programme was identified.

  • Major disclosed capital projects: new Thailand plant, KRW 56 bn (2025–2026); Pyeongtaek Plant 2 and logistics, KRW 41.5 bn of the 2021 rights issue; automation and lab equipment, KRW 24.0 bn; digital transformation, KRW 16.0 bn (IBK, Apr 2021).

  • Historical: capex jumped from KRW 5.1 bn (2014) to KRW 166.3 bn (2017) in the year of the Nu-World acquisition (Dealsite, Sep 2024).

Ratios

ROE: the trailing ROE was 28.5% as of 14 Oct 2026 (Valueline) and 26.7% on a Q1 2026 basis. A derived FY2025 ROE of about 24% uses controlling NI of KRW 123.1 bn over average controlling equity of about KRW 514 bn; the FY2024 equity is itself estimated from P/B, so treat this as approximate. Debt/equity on the FY2025 controlling-equity basis is about 1.9x (derived, approximate).

Commentary on trends, inflections and drivers

  1. FY2021 (expansion): The China online boom (Shanghai online share about 70%) and Korean e-commerce exports lifted operating profit 84%. Revenue was held back by the reversal of 2020 US hand-sanitiser demand.

  2. FY2022 (shock): Shanghai lockdowns cut China revenue about 15%. Ethanol and glycerine prices rose 38% and 74% respectively. Operating profit more than halved, and higher finance costs plus US losses produced a consolidated net loss.

  3. FY2023 (recovery and Korea inflection): Reopening, inbound tourism and indie-brand exports pushed Korean revenue above KRW 1 tn (+24%). The US moved toward ODM and reduced losses. At the standalone level, the KRW 256.4 bn provision on loans to US subsidiaries exposed the cumulative cost of the US strategy.

  4. FY2024 (K-beauty export super-cycle): Revenue +21.9% to KRW 2.17 tn and operating profit +51.6%, driven almost entirely by Korea (+28%) and Southeast Asia. China was flat and the US weak.

  5. FY2025 (record year, but uneven): Revenue +10.7% and operating profit +11.6%. Q3 2025 operating profit fell 1.6% because onboarding costs for a surge of new indie clients compressed Korean margins (Korea OP -13% in Q3). Indonesia fell 33% in Q3 amid domestic unrest and cheap imports. Net income rose 48% as non-operating drags eased.

  6. H1 2026 (broad-based acceleration): Q2 2026 revenue +27.5% was the first quarter in which every subsidiary grew. Korea topped KRW 500 bn, China grew about 33%, and the US grew 79% and turned profitable. Gross margin held at about 18% despite mix shifts. SG&A rose 32.1% on commissions and bad-debt expense, a watch item.

  7. Leverage: Net debt rose from KRW 705 bn to KRW 846 bn in FY2025, and leverage (about 3x EBITDA) remains elevated for a manufacturer. Drivers are the US funding, Cosmax East financing (RCPS→CB→early redemption with a KRW 110 bn intra-group loan), and new plant capex. Management has added KRW 100 bn of short-term bank lines (Sep 2026), so deleveraging depends on H2 2026 cash generation.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Entity revenue (KRW Bn)

Entity revenue (KRW Bn)FY2021FY2022FY2023FY2024FY2025

Cosmax Korea (standalone)

853.2854.01,057.61,357.71,526.4

Cosmax East (China, Shanghai + Guangzhou)

649.9550.5547.4574.3632.7

Cosmax West (USA)

135.0164.0139.9137.1132.6

Cosmax Indonesia

39.167.485.8113.297.7

Cosmax Thailand

19.9—25.643.573.2

Consolidated revenue

1,591.51,600.11,777.52,166.12,398.8

Results by Segment and Segment Margins & Growth (%)

Korea standaloneFY2021FY2022FY2023FY2024FY2025

Operating profit (KRW Bn)

77.5—86.8138.7154.6

Operating margin (%)

9.1—8.210.210.1

Revenue growth YoY (%)

11.00.123.828.412.4

Entity revenue growth (%)

Entity revenue growth (%)FY2023FY2024FY2025

Korea

23.828.412.4

China (East)

-0.64.910.2

USA (West)

-14.7-2.0-3.3

Indonesia

27.331.9-13.7

Thailand

—70.468.2

Share of entity revenue (%)

Share of entity revenue (%)FY2023FY2024FY2025

Korea

57.461.062.0

China

29.725.825.7

USA

7.66.25.4

Indonesia

4.75.14.0

Thailand

1.42.03.0

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

1,591.51,600.11,777.52,166.12,398.8

Revenue growth YoY (%)

15.10.511.121.910.7

Operating income (KRW Bn)

122.653.1115.7175.4195.8

EBITDA (KRW Bn)

——175244270

Net income, consolidated (KRW Bn)

34.4-16.437.888.4131.1

Net income to controlling shareholders (KRW Bn, derived from EPS)

—20.857.185.8123.1

EPS basic (KRW)

—1,8375,0367,56010,847

Dividend per share (KRW)

———2,3003,300

Operating margin (%)

7.73.36.58.18.2

EBITDA margin (%)

——9.811.311.3

Net margin, consolidated (%)

2.2-1.02.14.15.5

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Margin Analysis (%) (Quarterly)

Metric (KRW Bn)Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026

Revenue

558.0588.6623.6585.6601.0682.0794.9

Operating profit

39.851.360.842.740.953.073.7

Net profit (consolidated)

12.910.621.810.788.043.850.0

Gross profit

108.0————115.0142.5

Operating margin (%)

7.18.79.87.36.87.89.3

Balance Sheet and Balance Sheet (bps)

Metric (KRW Bn)FY2022FY2023FY2024FY2025

Total assets

1,396.41,557.11,933.72,125.4

Current assets

737.2821.6942.5975.0

Cash & equivalents

169.1256.9256.4192.3

Total borrowings (Yuanta, Apr 2026 basis)

——968.51,044.1

Net debt (Hanwha)

——705846

Controlling equity (derived from BPS)

———558

Dividends & Capital Returns

Metric (KRW Bn)FY2024FY2025

Dividends declared, total

26.137.4

Returns & Leverage Ratios (%) and Valuation Multiples (x)

RatioFY2023FY2024FY2025

ROA (%, derived)

2.65.16.5

Asset turnover (x, derived)

1.201.241.18

Net debt / EBITDA (x, derived)

—2.93.1

P/E on average price (x, Hanwha)

—29.020.2

P/B on average price (x, Hanwha)

—5.34.5

Region revenue (KRW Bn)

Region revenue (KRW Bn)FY2021FY2022FY2023FY2024FY2025

Korea

853.2854.01,057.61,357.71,526.4

China

649.9550.5547.4574.3632.7

USA

135.0164.0139.9137.1132.6

Indonesia

39.167.485.8113.297.7

Thailand

19.9—25.643.573.2

Region growth (%)

Region growth (%)FY2023FY2024FY2025

Korea

23.828.412.4

China

-0.64.910.2

USA

-14.7-2.0-3.3

Indonesia

27.331.9-13.7

Thailand

—70.468.2

Group Entities

Entity (KRW Bn)Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026

Korea

362.8420.5383.5359.7423.2518.4

China

162.7148.6140.0181.4194.7197.4

USA

28.730.036.937.042.053.8

Indonesia

29.620.921.525.722.728.9

Thailand

23.923.115.211.124.324.9

Valuation Snapshot

MetricValueDate / source

Last price

KRW 282,000

14 Oct 2026 (Valueline)

Market capitalisation

about KRW 3,229 bn

14 Oct 2026

52-week high / low

KRW 306,500 / KRW 141,000 (low on 26 Jun 2026)

Google Finance; Daum Finance

Return 1M / 3M / 6M / 1Y

+1.5% / +72.7% / +40.2% / +17.3%

7 Sep 2026 (WiseReport)

Average daily trading value (60D)

about KRW 18 bn

May 2026 (Yuanta, Kyobo)

Valuation Multiples (x) and Per-Share Data

Valuation metricFY2024FY2025

P/E (x)

29.020.2

P/B (x)

5.34.5

Dividend per share (KRW)

2,3003,300

Valuation Multiples

MultipleCosmaxKolmar Korea

Trailing P/E (x)

17.518.0

Forward P/E (x)

about 23.4 on Hanwha's May 2026 FY2026E EPS of KRW 12,048 (now likely stale given upgrades)

18.0 (fPER, Butler)

P/B (x)

5.03.3

EV/EBITDA FY2025 (x, derived)

about 15.1 (EV ≈ KRW 4,075 bn = mkt cap + FY2025 net debt; excludes minorities)

—

EV/Sales FY2025 (x, derived)

about 1.7

—

Dividend yield (%)

about 1.2 (KRW 3,300 / KRW 282,000)

0.6

ROE (%)

28.5 (TTM)

—

Analyst Ratings & Targets

BrokerRatingTarget price (KRW)Q3 2026E revenue (KRW Bn)Q3 2026E OP (KRW Bn)Date

Kyobo Securities

Buy

410,000820.078.2

7 Oct 2026

Hana Securities

Buy

380,000823.879.0

7 Oct 2026

SK Securities

Buy

370,000823.875.6

7 Oct 2026

Yuanta Securities

Buy

363,000815.083.0

7 Oct 2026

Market consensus (Q3 2026 OP)

———67.7

Oct 2026

Analyst Conclusions

Management guidance

No public numerical guidance was identified. Management's H2 2026 messaging centres on continued skincare strength, global K-beauty demand and new-client ramp-ups, with the US entering a "full turnaround phase". Brokers report Korea and the US tracking above internal guidance in Q3 2026.

Consensus expectations

  • Q3 2026 operating-profit consensus is KRW 67.7 bn. Leading brokers' October 2026 estimates of KRW 75.6–83.0 bn imply a further upward revision cycle.

  • Revenue growth expectations for Q3 2026 are about +39–41% YoY. Brokers expect Korea +45–47%, US about +70%, China +21–35%, Indonesia about +30% and Thailand +20–25%.

Bull case

  1. Operating leverage is only starting. With utilisation at 40–60% outside Korea, every overseas unit now growing double digits, and the US profitable, consolidated margins can move above the FY2025 level of 8.2%. Q3 2026 broker estimates imply roughly 9.2–10.2%.

  2. Structural share gain in a structural market. Korean cosmetics exports hit a record USD 11.4 bn in 2025. Cosmax's Korean revenue has nearly doubled since 2022 (KRW 854 bn to KRW 1,526 bn), and the L'Oréal MOU signals MNC outsourcing of innovation to Cosmax.

  3. Value capture and capital return. The Cosmax East IPO withdrawal removes double-listing risk. The 30% return policy and high-dividend status support ownership by domestic income investors.

Bear case

  1. The US history is the base rate. Ten years of losses, full capital impairment and repeated provisions argue that one profitable quarter (Q2 2026) is not proof of sustainability. Fresh guarantees (USD 50 m) show the unit still needs parent support.

  2. Balance-sheet strain. Net debt of about KRW 846 bn (about 3.1x EBITDA) is rising with the Cosmax East redemption loan, new short-term borrowing, Thai capex and the Keminova purchase. Net margins have historically been eroded by interest and FX.

  3. Sentiment risk after a doubling. The stock more than doubled from June 2026. Results misses produced drawdowns of about 27% (Aug 2025) and about 12.7% (Nov 2025). Indie-brand demand and colour exports are cyclical.

Catalysts and monitorables (next 12 months)

Q3 2026 results (about 10 Nov 2026): beat versus the KRW 67.7 bn consensus; Korea operating profit above KRW 60 bn; size of the CB-redemption one-off (about KRW 10 bn per SK).

US: sustainability of quarterly operating profit through Q3 and Q4 2026.

Thailand: ramp-up and utilisation of the new Bang Phli plant.

Keminova: first consolidated contribution and new EU client wins.

L'Oréal: conversion of the MOU into projects.

Capital structure: net-debt trajectory and refinancing of short-term lines.

FY2026 dividend: declaration (Feb–Mar 2027) under the 30% return policy.

Governance: succession signals at Cosmax BTI.

Margins: SG&A and bad-debt trends (Q2 2026 SG&A +32%).

Analyst verdict

Cosmax enters late 2026 at the strongest operating point in its history. Revenue has compounded at about 11% a year since FY2021, operating profit reached a record KRW 195.8 bn in FY2025, and H1 2026 showed something the company had not delivered in a decade: simultaneous growth and profitability across Korea, China, the US and Southeast Asia. The core asset, the Korean entity with roughly KRW 1.5 tn of revenue and about 10% margins, is a genuine global franchise. It is positioned as the outsourced R&D and production backbone of the K-beauty export boom and is now formally aligned with L'Oréal on innovation.

The dossier also documents why this company has historically traded at a discount to its operating story. Capital allocation abroad has been poor. The US cost hundreds of billions of won in provisions, and the China structure required two rounds of financial-investor buy-outs. Consolidated net margins have rarely exceeded 5%, and leverage of about 3x EBITDA is high for a contract manufacturer. Disclosure in English is thin, and several basic data points, including executive pay, cash-flow detail and ESG ratings, are hard to verify.

The investment question for the next twelve months is therefore less about demand, which brokers and the order book suggest is robust, than about conversion. Cosmax needs to turn record revenue into durable consolidated margins, free cash flow and deleveraging, while integrating Keminova and filling new Thai capacity without repeating the US pattern. At about 17.5x trailing earnings and about 15x EV/EBITDA, the market already prices substantial improvement after a doubling from the June 2026 low. Our synthesis: fundamentally strong and improving, with execution and balance-sheet risk that warrants position sizing discipline. The Q3 2026 print, US profitability through year-end, and the net-debt trend are the decisive tests of whether the 2026 inflection is structural rather than cyclical.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleTenure / backgroundSource

Lee Kyung-soo

Founder; Chairman, Cosmax Group

Founded the company in 1992. Silver Tower Order of Industrial Service Merit (2015).

Herald Business (2026)

Choi Kyoung (Choi Kyung)

Vice Chairman and Representative Director (CEO), Cosmax, Inc.

Signed the L'Oréal MOU (Sep 2026). Leads the supplier ESG programme.

L'Oréal (Sep 2026); Kukinews (Mar 2025); WEPs registry

Lee Byung-man (b. 1978)

Vice Chairman (promoted for 2026); co-representative director of Cosmax, Inc.; leads the group ODM business (R&D, production, quality, global clients)

Eldest son of the founder. Became largest shareholder of Cosmax BTI in May 2026 per Fortune

Creatrip (2026); TheVC; Fortune (2026)

Lee Byung-ju (b. 1979)

Vice Chairman and CEO, Cosmax BTI (holding)

Younger son. Oversees group strategy, new businesses (personalisation, beauty tech), M&A including Keminova

Creatrip; GlobeNewswire (Feb 2026)

Huh Min-ho

Senior Vice Chairman, Cosmax Group

Joined for the 2026 reshuffle to lead growth strategy and management infrastructure; retail background

Creatrip (2026)

Seo Seong-seok (Sung Suk Suh)

Co-founder; Chairwoman, Cosmax BTI

Holds about 21.62% (of BTI, per Creatrip)

Fortune; Creatrip

Kang Min-gu

CEO, Cosmax Thailand

Led the Bang Phli expansion

Korea Times (Apr 2025)

Major Shareholders

HolderStake (%)Date / source

Cosmax BTI and related parties (10–11 persons)

27.51

May 2026 (Kyobo, Hanwha)

National Pension Service

11.22

May 2026 (Kyobo)

GIC Private Limited (and 1 other)

6.3

May 2026 (Hanwha)

Employee Stock Ownership Association (and 1 other)

1.8

Jan 2025 (Hanwha)

Foreign ownership, total

35.16–39.4

Sep 2026 (WiseReport) / May 2026

Competitive Landscape

Key Competitors

CompetitorHQSegment overlapPositioning vs CosmaxRevenue (latest verified)

Kolmar Korea (161890)

Korea

Skincare / sun-care ODM; also pharma (HK inno.N), packaging, food

Main domestic rival; more diversified (cosmetics about 61% of revenue); strong in sun care

FY2025: KRW 2,722.4 bn revenue, KRW 239.6 bn OP, KRW 168.3 bn net (consolidated, all segments)

Cosmecca Korea

Korea

Colour and skincare ODM

Mid-tier Korean ODM

—

C&C International

Korea

Lip / colour ODM

Colour specialist

—

Intercos

Italy

Global makeup ODM

Leading Western makeup ODM; direct rival in Europe and US colour

—

Fareva (incl. makeup units)

France

Contract manufacturing for beauty and pharma

Large private European CMO

Not disclosed (private)

Nihon Kolmar

Japan

Cosmetics OEM/ODM

Japanese market

—

Toyo Beauty

Japan

Cosmetics OEM/ODM

Japanese market

—

Chinese domestic ODMs

China

Skincare and colour ODM for C-beauty

Price competition for Cosmax East

—

US contract manufacturers

USA

Skincare, OTC sun, colour

Incumbents in US indie and mass

—

In-house manufacturing (Amorepacific, LG H&H, large MNCs)

Various

Captive production

Substitutes for outsourcing

—

Peer Comparison FY2025

MetricCosmaxKolmar Korea

Revenue (KRW Bn)

2,398.82,722.4

Revenue growth (%)

10.711.0

Operating margin (%)

8.28.8

Net income (KRW Bn)

131.1168.3

R&D intensity (%)

5.54

about 6.5–7 (2023)

Market cap (KRW Bn, Oct 2026)

about 3,229

about 3,335

Company Snapshot

$1,688.1M

Revenue

1992

Founded

Registered seat in Hwaseong, South Korea

Headquarters

SWOT Analysis

Strengths

  • Scale leadership: FY2025 revenue of KRW 2,398.8 bn, the highest cosmetics ODM revenue reported. Korea entity revenue (KRW 1,526.4 bn) exceeds Kolmar Korea's standalone cosmetics revenue (about KRW 1,193 bn).
  • Profit engine in Korea: Korea OP of KRW 154.6 bn (10.1% margin) in FY2025, and quarterly revenue above KRW 500 bn for the first time in Q2 2026.
  • Blue-chip validation: supplier to L'Oréal since 2004, upgraded to a co-innovation MOU signed by L'Oréal's CEO (Sep 2026).
  • IP depth: about 2,000 patent filings and 820 registrations by end-2025; 1,839 functional approvals; R&D at 5.54% of sales.
  • Capacity and footprint: about 2.69 bn units across six countries, with spare utilisation (Shanghai 60%, US 60%) for operating leverage.
  • ESG credentials demanded by MNCs: EcoVadis Gold (top 2%), TCFD reporting, 10.4 GWh solar PPA.

Weaknesses

  • US value destruction: US unit in full capital impairment (liabilities KRW 314.4 bn vs assets KRW 112.2 bn, Q3 2025). KRW 256.4 bn provision on KRW 451.8 bn of standalone loans (2023).
  • Thin consolidated net margin: 5.5% in FY2025 and 2.1% in FY2023, held down by interest, FX and subsidiary losses.
  • Leverage: net debt of KRW 846 bn, about 3.1x EBITDA (FY2025). Additional borrowing and guarantees in Sep 2026.
  • Earnings volatility: Q3 2025 OP -1.6% and net -48%; share price falls of about 27% (Aug 2025) and about 12.7% (Nov 2025) after results.
  • Low Guangzhou utilisation (about 40%) and uneven China profitability (net loss in Q2 2025).
  • Opacity: limited English disclosure; segment profit, pay and cash-flow detail are hard to access.

Opportunities

  • US turnaround: +79% revenue and first operating profit in Q2 2026; brokers forecast +70% in Q3 2026.
  • Europe via Keminova: 51% of a 20 m-unit Brescia plant with derma and medical-device credentials; "Made in Italy" K-beauty.
  • L'Oréal co-development: potential to shift from SKU orders to programme-level innovation contracts.
  • SEA capacity and OBM: Thailand at up to 230 m units; Indonesia recovery (+38% in Q2 2026); Vietnam and India extension.
  • Raw-material internalisation: company-claimed about 30% cost saving versus imports, a potential margin lever.
  • Simplified China structure: FI exit and IPO withdrawal let China value accrue fully to Cosmax shareholders.

Threats

  • Indie-brand cyclicality: onboarding costs hit Korea OP (-13% in Q3 2025) and weak colour exports hit Q1 2026.
  • Competition: Kolmar Korea's stronger margins (8.8% vs 8.2%) and US capacity build; European ODMs in Cosmax's new market.
  • China macro and local ODMs: China revenue still below FY2021's KRW 649.9 bn in FY2025.
  • Indonesia volatility: -33% in Q3 2025 on unrest and imports.
  • Funding and FX risk: KRW 91.2 bn of guarantees, USD 50 m for Cosmax West, KRW 100 bn of new short-term debt.
  • Valuation and sentiment: shares more than doubled from the June 2026 low (KRW 141,000) to above KRW 300,000. Any miss could trigger sharp de-rating, as in Aug and Nov 2025.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
27 Mar 2025Groundbreaking of new Bang Phli, Thailand plant (KRW 56 bn)Triples Thai capacity; SEA hub
2 Apr 2025Becomes UN WEPs signatoryESG / diversity commitment
13 May 2025Q1 2025: revenue KRW 588.6 bn (+11.7%), OP KRW 51.3 bn (+13.0%), net KRW 10.6 bn (-45.8%) on non-operating lossesRecord Q1 margin; below-the-line drag
11 Aug 2025Q2 2025: record revenue KRW 623.6 bn (+13.1%), OP KRW 60.8 bn (+30.2%); net KRW 21.8 bn (-38.1%) on interest and FXFirst quarter above KRW 600 bn revenue and KRW 60 bn OP
Aug 2025Shares fall about 27% after Q2 results on valuation and seasonality concernsSentiment volatility
30 Sep 2025Raw-material supplier partnership meetingSupports ingredient-internalisation strategy
10 Nov 2025Q3 2025: revenue KRW 585.6 bn (+10.5%), OP KRW 42.7 bn (-1.6%), net KRW 10.7 bn (-48.3%); Korea OP -13% on onboarding costs; Indonesia -33%Margin wobble
11 Nov 2025Shares fall about 12.7% intraday to KRW 165,400; brokers cut targetsEarnings-visibility concern
Nov 2025Corporate Value-up Plan: 30% shareholder return through 2028Capital-allocation clarity
10 Dec 2025EcoVadis Gold for the 2nd year (top 2%); first TCFD reportESG credential for MNC clients
Late 20252026 executive reshuffle: Lee Byung-man and Lee Byung-ju become vice chairmen; Huh Min-ho joins as senior vice chairman; 31 executives appointedSuccession architecture
23 Feb 2026FY2025 results: record revenue KRW 2,398.8 bn (+10.7%), OP KRW 195.8 bn (+11.6%)Second consecutive record year
23 Feb 2026SPA for 51% of Keminova (Italy)First European production base
24 Feb 2026Shinhan cuts target P/E from 22x to 16x on sector de-rating; maintains KRW 240,000 targetSector multiple compression
5 Mar 2026Samsung Securities NDRInvestor outreach
26 Mar 2026Qualifies as a "high-dividend company" (first among Korean cosmetics ODMs); FY2025 DPS KRW 3,300 (+43.5%), total KRW 37.4 bnShareholders eligible for separate dividend taxation
Apr 2026Keminova closing; management control securedConsolidation from Q2 2026
12 May 2026Q1 2026: revenue KRW 682.0 bn (+15.9%), OP KRW 53.0 bn (+3.3%), net KRW 43.8 bn (+312%); China record revenue; colour exports weakTop-line beat, margin miss
18 May 2026Solar PPA with Hanwha Solutions (10.4 GWh a year)Decarbonisation
May 2026Lee Byung-man becomes Cosmax BTI's largest shareholder (Fortune)Succession signal
21 May 2026Yuanta Corporate DayInvestor outreach
26 Jun 2026Shares hit 52-week low of KRW 141,000Trough before re-rating
Jul 2026Keminova PMI: R&D reorganised; joint eco-material projectsIntegration progress
11 Aug 2026Q2 2026: record revenue KRW 794.9 bn (+27.5%), OP KRW 73.7 bn (+21.2%), net KRW 50.0 bn (+129%); Korea above KRW 500 bn; US first operating profitInflection in overseas profitability
12 Aug 2026Shares jump about 18% intraday to KRW 260,000Re-rating begins
Late Aug – 1 Sep 2026Board approves KRW 110 bn loan to Cosmax East, KRW 100 bn additional short-term borrowing, and KRW 91.2 bn of guarantees (including USD 50 m for Cosmax West)Funding of CB redemption and US working capital
Early Sep 2026Cosmax East IPO formally withdrawn with FI agreementRemoves double-listing overhang
8–9 Sep 2026L'Oréal Groupe MOU signed in ParisStrategic validation; co-innovation
Sep 2026New Thailand plant scheduled to begin operationsCapacity to 230 m units
Sep–Oct 2026Shares reach a record high (52-week high KRW 306,500)Market cap above KRW 3 tn
7 Oct 2026Q3 2026 previews: revenue KRW 815–824 bn; OP KRW 75.6–83.0 bn versus consensus KRW 67.7 bn; targets raised to KRW 363,000–410,000 (Yuanta, SK, Hana, Kyobo)Expected record Q3 in a seasonally weak quarter
14 Oct 2026Close at KRW 282,000; market cap about KRW 3.23 tnCurrent valuation reference

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

6 charts
Entity Revenue: Cosmax Korea (standalone) rose from KRW 853.2 Bn in FY2021 to KRW 1,526.4 Bn in FY2025.
Cosmax, Inc. — Entity Revenue
Series (KRW Bn)FY2021FY2022FY2023FY2024FY2025
Cosmax Korea (standalone)853.28541,057.61,357.71,526.4
Cosmax East (China, Shanghai + Guangzhou)649.9550.5547.4574.3632.7
Cosmax West (USA)135164139.9137.1132.6
Cosmax Indonesia39.167.485.8113.297.7
Cosmax Thailand19.9—25.643.573.2
Consolidated revenue1,591.51,600.11,777.52,166.12,398.8

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Cosmax IR: Q4 2024 results deck (Feb 2025)
  2. Cosmax IR: Q3 2025 results deck (Nov 2025), via AlphaSquare
  3. Cosmax IR: Q4 2025 results / Samsung NDR deck (Feb–Mar 2026)
  4. Cosmax Corporate Value-up Plan (Nov 2025)
  5. Cosmax global production page
  6. L'Oréal Groupe press release (9 Sep 2026)
  7. GlobeNewswire / Adnkronos, Keminova acquisition (Feb 2026)
  8. ICE / ITA, Keminova PMI (Jul 2026)
  9. Dealsite, FY2025 results (Feb 2026)
  10. Dealsite, Q2 2026 results (Aug 2026)
  11. Dealsite, Q3 2025 results (Nov 2025)
  12. Dealsite, FY2021 / FY2022 / FY2023 results · dealsite.co.kr · dealsite.co.kr
  13. Dealsite, US strategy and Europe pivot (Mar 2026)
  14. Dealsite, Cosmax East capital reduction (Feb 2025)
  15. Herald Business, dividend and high-dividend status (Mar 2026)
  16. Herald Business, founder history (2026)
  17. Herald Business, Hanwha Solutions PPA (May 2026)
  18. KET, Cosmax East CB redemption (Sep 2026)
  19. TokenPost, Cosmax East IPO withdrawal
  20. Korea JoongAng Daily, Thailand plant (Apr 2025)
  21. Kukinews, EcoVadis Gold (Dec 2025)
  22. Sidae, R&D and raw-material strategy (Mar 2026)
  23. Fortune, Most Powerful Women Asia 2026 (Sung Suk Suh)
  24. Creatrip, 2026 executive reshuffle
  25. Hanwha Investment & Securities report (May 2026)
  26. Yuanta Securities report (Apr 2026)
  27. Eugene Investment report (May 2026)
  28. StockHub broker summaries (Oct 2026) · stockhub.kr · stockhub.kr · stockhub.kr
  29. Valueline, valuation and balance sheet (Oct 2026) · valueline.co.kr
  30. WiseReport company profile (Sep 2026)
  31. Akros event register (Sep 2026 board approvals)
  32. Dealsite, Kolmar Korea FY2025 results (Feb 2026)
  33. Dailian, Nu-World acquisition (Nov 2017)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.